Biocon Places Bet On Insulins, Talks Up Oral Insulin And MAbs
This article was originally published in PharmAsia News
Executive Summary
In the wake of its “amicable” break up with Pfizer, it may be a rough ride for India’s Biocon in the short term but the company is building a formidable portfolio of insulin and analogs that could secure its future.